Off-target decoding of a multitarget kinase inhibitor by chemical proteomics.
Unbiased: Chemical proteomics was used to profile compound interactions in an unbiased fashion. We present here the application of different compound-immobilization routes for decoding nonprotein kinase off-targets of the multitarget kinase inhibitor C1, which interacts with distinct compound moieties. Since the approval of the first selective tyrosine kinase inhibitor, imatinib, various drugs have been developed to target protein kinases. However, due to a high degree of structural conservation of the ATP binding site, off-target effects have been reported for several drugs. Here, we report on off-target decoding for a multitarget protein kinase inhibitor by chemical proteomics, by focusing on interactions with nonprotein kinases. We tested two different routes for the immobilization of the inhibitor on a carrier matrix, and thus identified off-targets that interact with distinct compound moieties. Besides several of the kinases known to bind to the compound, the pyridoxal kinase (PDXK), which has been described to interact with the CDK inhibitor (R)-roscovitine, was captured. The PDXK-inhibitor interaction was shown to occur at the substrate binding site rather than at the ATP binding site. In addition, carbonic anhydrase 2 (CA2) binding was demonstrated, and the determination of the IC(50) revealed an enzyme inhibition in the submicromolar range. The data demonstrate that different compound immobilization routes for chemical proteomics approaches are a valuable method to improve the knowledge about the off-target profile of a compound.
Bayer Schering Pharma AG, Global Drug Discovery, 13342 Berlin, Germany. enrico.missner@bayerhealthcare.com
Enrico
E
Missner
Inke
I
Bahr
Volker
V
Badock
Ulrich
U
Lücking
Gerhard
G
Siemeister
Peter
P
Donner
D001665:Binding Sites; D024402:Carbonic Anhydrase II / Q000037:antagonists & inhibitors / Q000378:metabolism; D045744:Cell Line, Tumor; D019295:Computational Biology; D006367:HeLa Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D040901:Proteomics; D011687:Purines / Q000737:chemistry; D011731:Pyridoxal Kinase / Q000037:antagonists & inhibitors / Q000378:metabolism; D011743:Pyrimidines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D000077546:Roscovitine; D013449:Sulfonamides / Q000737:chemistry
D047428:Protein Kinase Inhibitors; D011687:Purines; D011743:Pyrimidines; D013449:Sulfonamides; D000077546:Roscovitine; D011731:Pyridoxal Kinase; D024402:Carbonic Anhydrase II